Business Wire

RIDDLE&CODE

17.3.2022 10:17:06 CET | Business Wire | Press release

Share
ZENBRIDGE, Developed by Dyne.org, RIDDLE&CODE and InfoCert, Selected for Phase 2 of the European Blockchain Pre-Commercial Procurement

The consortium formed by Dyne.org, RIDDLE&CODE and InfoCert has entered the second phase of the European Blockchain Services Infrastructure (EBSI) project and will receive support to further develop and test its multilayered blockchain stack ZENBRIDGE.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005181/en/

Led by the European Commission and 29 member countries that collaborate as a European Blockchain Partnership (EBP), EBSI aims to develop highly secure and compliant cross-border public services on a European level. This involves overcoming gaps in the existing blockchain applications and delivering more demanding solutions that reduce environmental footprint and comply with EU legal frameworks such as the GDPR. The second phase of the project was launched on December 20, 2021, and will run until the end of June 2022.

Some use cases include management and exploitation of data, tracking of digital records and the rights associated with them, automation of tasks through smart contracts and development of incentive models through tokenization of both physical and digital assets.

ZENBRIDGE, a state-of-the-art decentralized system, offers distributed, secure execution of smart contracts and is integrated with blockchain frameworks such as BigchainDB, PlanetMINT, Ethereum, Hyperledger Fabric, Hyperledger Sawtooth and Bitcoin. The system is designed to deliver high-velocity performance, ensure sustainability and provide superior levels of data sovereignty as well as interoperability between various blockchain networks and legacy systems.

During this second phase, research and development results will be lab-tested. Based on these outcomes, a minimum of three projects will be selected for the final Phase (2B), which will run for an additional 12 months and result in real-world field testing.

Quotes from the consortium members:

Thomas Fürstner (Founder & CTO, RIDDLE&CODE): “The expertise of our consortium will hopefully convince the European Commission to make use of blockchain technology as a multipurpose tool to secure both the value of digital assets and data. At the ‘layer zero’, RIDDLE&CODE will work to connect productive machines and sensors with the security of banking-grade backends. This will allow us to establish trusted digital product passports for physical items in motion across Europe and ensure compliance with the European regulatory frameworks in a transparent way.”

Denis “Jaromil” Roio , (Founder and CTO of Dyne.org): “In our success within the EBSI procurement process, we see a big opportunity to provide the European ICT industry with environmentally sustainable solutions that are free and open to community-based adoption models. We leverage cryptography beyond some common financial sector use cases, making it easy to retrofit and recycle legacy infrastructure. Our solution is free from the speculation and waste of crypto-markets, supports computation on low-power embedded hardware and supports future-proof building blocks that are quantum-resistant. With the ZENBRIDGE stack, a developer can go from a smart contract to a ready-to-use wallet app implementation for digital product passports in a week.”

Carmine Auletta (Chief Strategy and Innovation Officer, InfoCert - Tinexta Group): “We’re pleased with the results achieved by the consortium in Phase 1 and proud of the support and trust placed in us to further develop the project in its second phase. Distributed Ledger Technologies will play an important role in the EU digital market and a key component to their market uptake will inevitably be played by their Governance & Trust Framework. Our consortium partners have demonstrated extraordinary technical expertise in distributed ledger technologies, while InfoCert has very distinctive experience in creating Trust Frameworks. Joining forces has proved crucial to ZENBRIDGE’s success.”

About RIDDLE&CODE

RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.

More information: www.riddleandcode.com

About Dyne.org

Dyne.org is a non-profit foundation dedicated to free and open-source software and community development with 20 years of expertise in developing applications used worldwide. With the motto “we are free to share code and we code to share freedom”, its projects include independent streaming software for free speech, privacy tools for activists and GNU/Linux distributions.

More information: dyne.org

About InfoCert

InfoCert, Tinexta Group, is the largest European certification authority, active in over twenty countries. The company provides services in digitisation, eDelivery, Digital Signature and digital preservation of documents and is an accredited AgID digital identity operator in the area of SPID (Public System for the management of Digital Identity). The company holds a 60% stake in CertEurope, the biggest certification authority in France; a 51% stake in Camerfirma, one of the principal Spanish certification authorities; a 16.7% stake in Authada, a leading-edge German Identity Provider; and 80% of Sixtema S.p.A.

More information: infocert.digital

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye